
|Videos|September 21, 2016
Were PCSK9 Inhibitors Overhyped?
Author(s)Lauren Santye, Assistant Editor
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.
Advertisement
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Sotatercept Demonstrates Significant Reduction in Morbidity and Mortality Across Broader PAH Risk Groups
2
Enhancing Early Cholesterol Detection and Management in Young Adults
3
Integrating Combination Therapies for Type 2 Diabetes and CKD
4
Building a Unified Approach to Cardio Kidney Metabolic Health
5












































































































































































































